Download Free State Of The Art Research On C1q And The Classical Complement Pathway Book in PDF and EPUB Free Download. You can read online State Of The Art Research On C1q And The Classical Complement Pathway and write the review.

C1q is the target recognition protein of the classical complement pathway and a major connecting link between innate and acquired immunity. As a charge pattern recognition molecule of innate immunity, C1q can engage a broad range of ligands derived from self, non-self and altered self via its heterotrimeric globular (gC1q) domain and thus trigger the classical complement pathway. The trimeric gC1q signature domain has been identified in a variety of non-complement proteins that can be grouped together as a C1q family. C1q circulates in serum as part of the C1 complex, in association with a catalytic tetrameric assembly of two homologous yet distinct serine proteases, C1r and C1s. Binding of C1q to appropriate targets leads to sequential activation of C1r and C1s, the latter being able to cleave complement components C4 and C2 thereby triggering the complement cascade. Activation of the classical pathway plays an important role in innate immune protection against pathogens and damaged elements from self. However, its involvement has been shown in various pathologies including ischemia-reperfusion injury and hereditary angioedema. Unexpected roles for the classical pathway have also been discovered recently, linked to both physiological and pathological aspects of development, including brain and cancer cells. These new perspectives should arouse renewed interest in a search for specific inhibitors of the classical pathway. In addition, C1q has recently been shown to have a number of functions that are independent of the activation of the classical pathway. This research topic is aimed at providing a state-of-the-art overview of the classical pathway, including, but not restricted to emerging functions of C1q and of the C1 complex, as well as pathological consequences of C1 activation or of the presence of anti-C1q autoantibodies . Contributions are included in the areas such as structural basis of C1q ligand recognition, C1q family proteins, inhibitors of the classical pathway identified in pathogens and improved derived inhibitors, structural determinants of the substrate specificities of C1r and C1s, elucidation of the architecture of C1, structural and functional homology of C1 with the initiating complexes of the lectin complement pathway, and novel involvement of C1q in processes such as ageing, cancer, synaptic pruning, and pregnancy.
This completely updated and expanded 2nd edition of Systemic Lupus Erythematosus, A Manual includes topics not covered previously with contributors who are at the forefront of each specific topic and with a global appeal. Each chapter is short and is presented critically with selected references, which should be valuable to a wider audience. This book combines basic with clinical science to help internists and specialists in the diagnosis and management of patients with SLE. It is a quick referral for people in the pharmaceutical industry in their efforts to bring much-needed drugs. It provides all the needed information to basic researchers old and new alike, who wish to enter the field of lupus and systemic autoimmunity in general. - Focused state-of-the-art chapters prepared by top-notch experts in the field - Latest understanding of cellular, molecular, biochemical aspects of disease pathogenesis - Advanced aspects of genetic, microbiome, environmental, hormonal, and immunological contribution to the expression of the disease - Current understanding of clinical features of the disease - Recent efforts to develop new treatments
This book provides updated information to scientists and clinicians on taeniosis/cysticercosis, a parasitic infection caused by eating undercooked beef or pork that is a serious health and veterinary problem in many developing countries. It discusses incidence, risk factors, diagnosis, immunology, symptoms, rare manifestations, and advances in treatment including vaccination and novel drug therapies.
Covering all the basic and clinical concepts you need to know for your coursework and USMLEs, Immunology, 9th Edition, offers a well-illustrated, carefully structured approach to this complex and fast-changing field. Carefully edited and authored by experts in both teaching and research, it provides cutting-edge, consistent coverage that links the laboratory and clinical practice. A user-friendly, color-coded format, including key concept boxes, explanatory diagrams, and nearly 200 photos to help you visually grasp and retain challenging concepts. Explains the building blocks of the immune system - cells, organs, and major receptor molecules - as well as initiation and actions of the immune response, especially in a clinical context. Includes extensive updates to clinical information, including recent clinical approaches in cancer immunology, transplantation, autoimmunity, hypersensitivity, and more. Features a reorganized format that presents immunology in the order in which is typically taught and learned, better integrating basic and clinical immunology. Covers new topics such as innate lymphoid cells, antibody-based therapies and antibody engineering, innate immunity and its components, the genetics of immunologically-based diseases and personalized medicine, and immunotherapeutic agents for the treatment of cancer. Provides Critical Thinking boxes, chapter-opening summaries, and case-based and USMLE-style questions that provide effective review and quick practice for exams – plus more learning opportunities online, including USMLE-style questions and clinical cases. Includes extensive updates to clinical information, including recent clinical approaches in cancer immunology, transplantation, autoimmunity, hypersensitivity, and more. Covers new topics such as innate lymphoid cells, antibody-based therapies and antibody engineering, innate immunity and its components, the genetics of immunologically-based diseases and personalized medicine, and immunotherapeutic agents for the treatment of cancer.
The complement system is a multi-tasking gatekeeper of innate immunity thatintricately interacts with other key defense systems, such as the endothelial barrier,contact activation and coagulation systems, in maintaining tissue immunosurveillanceand homeostasis. Its rapid and forceful activation in the bloodstream not onlyensures the effective containment of microbial infections through potent cytolyticmechanisms, but also alerts the adaptive immune compartment to ensure the mountingof a proper humoral immune response against foreign antigens. However, there isa lurking ‘dark side’ that can lead complement astray, fueling a self-perpetuatingvicious cycle of inflammation, exuberant immune activation and irreversible tissueinjury that collectively exacerbate both acute and chronic pathologies. Indeed,complement dysregulation or excessive activation have been widely recognized askey pathogenic drivers in a wide spectrum of inflammatory or immune-mediateddiseases. Targeted modulation of the complement system at various points ofthe cascade has revealed promising therapeutic targets for ameliorating diseasescores in a number of conditions ranging from ocular, neurodegenerative andthromboinflammatory disorders, to cancer, periodontal diseases, chronic hemolyticanemias, ischemia-reperfusion organ injury, antibody-mediated transplant rejectionand hemodialysis-triggered inflammation. Elegant pre-clinical studies employing a diversified toolbox of highly specificcomplement inhibitors in rodent or primate models of disease have opened newavenues of therapeutic exploration by providing proof of concept for the therapeuticefficacy of complement modulation. At the same time, the clinical experience gainedduring this last decade with the sole complement-specific drug currently in the clinic,eculizumab, has rekindled the interest of biopharmaceutical companies in developingnew and potent complement therapeutics for complement-driven diseases. In this respect, the complement field is witnessing a new surge of clinical trialsthat are evaluating the safety, PK/PD profile and clinical efficacy of promising drugcandidates in a number of clinical conditions driven by complement imbalance orover-activation.
This textbook provides a unique support in gaining essential knowledge on the immune response, its diagnosis and its modification by drugs and chemicals. The first section of the book, covering a basic introduction to immunology and its relevance for human disease, has been updated to accommodate new immunological concepts. The second section on immunodiagnostics has been further expanded to describe widely used molecular techniques and is followed by a systematic coverage of drugs affecting the immune system, revised to cover recent developments. The book concludes with a chapter on immunotoxicology. This third edition continues the unique format dealing with four related topics in a single volume, obviating the need to refer to several different textbooks. New aids to the reader include a two-column format, glossaries of technical terms and appendix reference tables. The emphasis on illustrations is maintained from the first edition.
This book is a printed edition of the Special Issue "PrPSc prions: state of the art" that was published in Pathogens
Comprehensive Biomaterials II, Second Edition, Seven Volume Set brings together the myriad facets of biomaterials into one expertly-written series of edited volumes. Articles address the current status of nearly all biomaterials in the field, their strengths and weaknesses, their future prospects, appropriate analytical methods and testing, device applications and performance, emerging candidate materials as competitors and disruptive technologies, research and development, regulatory management, commercial aspects, and applications, including medical applications. Detailed coverage is given to both new and emerging areas and the latest research in more traditional areas of the field. Particular attention is given to those areas in which major recent developments have taken place. This new edition, with 75% new or updated articles, will provide biomedical scientists in industry, government, academia, and research organizations with an accurate perspective on the field in a manner that is both accessible and thorough. Reviews the current status of nearly all biomaterials in the field by analyzing their strengths and weaknesses, performance, and future prospects Covers all significant emerging technologies in areas such as 3D printing of tissues, organs and scaffolds, cell encapsulation; multimodal delivery, cancer/vaccine - biomaterial applications, neural interface understanding, materials used for in situ imaging, and infection prevention and treatment Effectively describes the many modern aspects of biomaterials from basic science, to clinical applications